钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病肾病的研究进展  

Research progress of sodium-dependent glucose transporter 2 inhibitors in the treatment of diabetic nephropathy

作　　者：李诗琪 范瑛[1] 汪年松[1] LI Shi-qi;FAN Ying;WANG Nian-song(Department of Nephrology,Shanghai Jiaotong University Affiliated Sixth People's Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院肾内科,上海200233

出　　处：《世界临床药物》2020年第10期753-757,共5页World Clinical Drug

基　　金：国家自然基金面上项目(81670657、81870504、81870468);上海交通大学医学院“临床专职科研队伍”人才计划(20192833);上海市徐汇区重点课题(SHXH201648);上海市卫计委资助课题(2019SY018)。

摘　　要：糖尿病肾病(diabetic nephropathy)的治疗是预防和延缓终末期肾脏病(end-stage renal disease)的重要手段。钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporter,SGLT)2抑制剂是一种新型口服降糖药物,除可以有效降低糖尿病患者血糖以外,还具有降低血压、心血管事件发生风险和保护肾脏的作用。本文就SGLT2抑制剂的作用机制及临床应用作一综述。Diabetic nephropathy (DN) treatment has been the key of end-stage renal disease (ESRD) prevention.Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are a new oral hypoglycemic drug,which have shown potentials in decreasing blood pressure,reducing cardiovascular risk,and kidney protection as well as lowering plasma glucose.This article reviewed the mechanism of SGLT2 and the advanced clinical application in treating patients with DN.

关 键 词：糖尿病肾病 钠-葡萄糖协同转运蛋白抑制剂 药物治疗 

分 类 号：R692[医药卫生—泌尿科学] R977.24[医药卫生—外科学]